AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
10 June 2013 | By AstraZeneca
AstraZeneca has entered into a definitive agreement to acquire Pearl Therapeutics...
List view / Grid view
News
Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia
8 June 2013 | By Boehringer Ingelheim
New findings presented...
Gilead announces U.S. FDA priority review designation for sofosbuvir for the treatment of hepatitis C
7 June 2013 | By Gilead Sciences
Gilead Sciences announced that the U.S. FDA has granted priority review...
Boehringer Ingelheim pioneers biopharmaceuticals move to China
6 June 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company...
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)
6 June 2013 | By GlaxoSmithKline
A joint advisory committee to the U.S. FDA voted to continue to make Avandia available...
GGC reports autism discovery
5 June 2013 | By Greenwood Genetic Center
Researchers have reported an important discovery in the understanding of autism which was published this week in Molecular Autism...
ORIGIN results on Lantus® cardiovascular safety integrated into European Union product label
5 June 2013 | By Sanofi
ORIGIN was a landmark, seven-year clinical trial...
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
5 June 2013 | By Novartis
Gilenya improved the key measures...
U.S. FDA grants priority review for Metreleptin
4 June 2013 | By Bristol-Myers Squibb Company
Metreleptin, an investigational agent for treatment of metabolic disorders associated with rare forms of LD...
Two real-world European studies of Abbott’s minimally invasive MitraClip® device demonstrate positive outcomes for patients with MR
4 June 2013 | By Abbott
Publication of positive outcomes...
AstraZeneca announces top-line results from Phase III OSKIRA Trials of FOSTAMATINIB
4 June 2013 | By AstraZeneca
AstraZeneca announced top-line results from OSKIRA-2 and OSKIRA-3...
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU
3 June 2013 | By Teva Pharmaceutical Industries Ltd
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU for the reduction of CIN...
Sanofi provides update on Phase 3 studies of two investigational compounds
3 June 2013 | By Sanofi
Sanofi announced topline results of two Phase 3 clinical studies...
AstraZeneca enters agreement with Hanmi Pharmaceuticals and Amneal Pharmaceuticals in US NEXIUM patent litigation
3 June 2013 | By AstraZeneca
AstraZeneca enters new agreement...
LUME-Lung 1: Nintedanib* plus chemotherapy extends the life of lung cancer patients with adenocarcinoma
3 June 2013 | By Boehringer Ingelheim
LUME-Lung 1 results represent the first advance in almost a decade...
